Systemic and local evidence for complement involvement in chronic spontaneous urticaria.

ABSTRACT:

Background

The pathogenesis of chronic spontaneous urticaria (CSU), including the mechanism of action of omalizumab, remain unclear. We hypothesized complement system involvement given the often fast clinical response induced by treatment, including omalizumab. Therefore, we assessed the role of various complement factors surrounding omalizumab treatment.

Methods

Thirty CSU patients (median age 42 [range 21-70]; 73 % female) with a median once daily Urticaria Activity Score over 7 days (UAS7) score at baseline of 31.5 points were enrolled. Treatment consisted of six administrations of 300 mg omalizumab every 4 weeks succeeded by a follow-up period of 12 weeks. Four punch skin biopsies were taken per patient; at baseline from lesional skin, at baseline from nonlesional skin,

SUBMITTER: Alizadeh Aghdam M 

PROVIDER: S-EPMC8254579 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature